Company news

Microbot Medical Inc. news in 2024

Microbot Medical Inc.'s news releases, calls and decks from 2024, newest first.

View company

Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®

December 29, 2024

Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System

December 9, 2024

Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025

October 14, 2024

Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up

September 29, 2024

Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

September 16, 2024

Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System

August 21, 2024

Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization

August 12, 2024

Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

July 17, 2024

Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial

July 8, 2024

Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial

July 7, 2024

Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial

July 2, 2024

Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial

June 19, 2024

Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial

June 16, 2024

Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

June 3, 2024

Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial

June 2, 2024

Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

June 2, 2024

Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™

April 28, 2024

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

February 4, 2024

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters

January 29, 2024

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

January 17, 2024

Decks in 2024